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ABSTRACT
Although many efforts have recently contributed to improve our knowledge of 
molecular pathogenesis of multiple myeloma (MM), the role and significance of long 
non-coding RNAs (lncRNAs) in plasma cells (PC) malignancies remains virtually absent. 
To this aim, we developed a custom annotation pipeline of microarray data investigating 
lncRNA expression in PCs from 20 monoclonal gammopathies of undetermined 
significance, 33 smoldering MM, 170 MM, and 36 extra-medullary MMs/plasma cell 
leukemia patients, and 9 healthy donors. Our study identified 31 lncRNAs deregulated 
in tumor samples compared to normal controls; among these, the upregulation of 
MALAT1 appeared associated in MM patients with molecular pathways involving cell 
cycle regulation, p53-mediated DNA damage response, and mRNA maturation processes. 
Furthermore, we found 21 lncRNAs whose expression were progressively deregulated 
trough the more aggressive stages of PC dyscrasia, suggesting a possible role in the 
progression of the disease. Finally, in the context of molecular heterogeneity of MM, 
we identified a transcriptional fingerprint in hyperdiploid patients, characterized by the 
upregulation of lncRNAs/pseudogenes related to ribosomal protein genes, known to be 
upregulated in this molecular group. Overall, the data provides an important resource 
for future studies on the functions of lncRNAs in the pathology.
INTRODUCTION
Multiple myeloma (MM) is a malignant proliferation 
of antibody-secreting bone marrow plasma cells (PCs) 
characterized by a wide clinical spectrum ranging from 
the presumed pre-malignant condition called monoclonal 
gammopathy of undetermined significance (MGUS), to 
smoldering MM (SMM), truly overt and symptomatic MM, 
and extra-medullary myeloma/plasma cell leukemia (PCL) 
[1–3]. Despite the remarkable improvements in treatment 
and patient care [4], MM remains an incurable disease.
During the years that have followed human genome 
sequencing, it has become evident that over 90% of 
the genome is actively transcribed [5, 6], the majority 
of transcripts being represented by non-coding RNA 
(ncRNA) and therefore not translated into proteins. 
NcRNAs are broadly divided into short (<200 nt) and long 
(>200 nt) transcripts. Dysregulation of short ncRNAs, 
particularly miRNAs, has been reported to occur virtually 
in all types of cancer, including MM, highlighting the 
usefulness of miRNA profiling in diagnosis, prognosis, 
and in predicting response to therapy [7, 8]. Notably, 
miRNAs are currently considered both emerging 
therapeutic targets and innovative intervention tools in 
cancer including MM [9–11].
Long non-coding RNAs (lncRNAs) are a very 
heterogeneous group that lack mRNA properties, although 
they exhibit a structure and biogenesis that does not differ 
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greatly from mRNAs: indeed, they can be polyadenylated 
and may operate in either nuclear and/or cytoplasmic 
fractions. LncRNAs represent more than half of the 
mammalian noncoding transcriptome and are involved 
in many biological processes, such as transcriptional 
gene regulation, maintenance of genomic integrity, 
X-chromosome inactivation, genomic imprinting, cell 
differentiation, and development [12]. Among lncRNAs, 
there are also pseudogenes that have lost their protein-
coding ability or are otherwise no longer translated; 
however, they may be functional, similar to other kinds 
of non-coding RNA, and can have a regulatory role [13]. 
LncRNAs can also be classified based on their location 
relative to nearby protein-coding genes. They originate 
from introns, exons, intergenic, promoter regions, 3’- 
and 5’-UTRs; therefore they may represent antisense, 
bidirectional, or sense-overlapping sequences of specific 
genes [14, 15]. Several lncRNAs exhibit temporal and 
spatial expression patterns; moreover, their expression 
can be restricted to particular tissue or cell cycle stages, 
indicating diverse biological roles for lncRNAs [16]. 
Deregulation of distinct lncRNAs has been reported to 
promote tumor formation, progression, and metastasis in 
many types of cancer, including hematologic malignancies 
[17, 18]. The number of known human lncRNA transcripts 
is still evolving. LNCipedia v3.1 is the largest integrated 
repository containing 111,685 human annotated lncRNAs, 
with many loci generating multiple transcripts [19].
The knowledge of the role of lncRNAs in MM is 
virtually absent. A recent paper investigated lncRNAs 
as biomarkers for predicting survival in MM patients 
[20]; in addition, MALAT1 (metastasis-associated lung 
adenocarcinoma transcript 1), a putative oncogenic lncRNA 
overexpressed in several solid tumors [21, 22], has been 
found overexpressed in MM and may represent a marker 
to predict MM progression [23]. Moreover, it is expressed 
in bone marrow mononuclear cells of newly diagnosed 
myeloma patients [23]. Finally, preliminary evidence has 
suggested deregulated levels of circulating lncRNAs in MM 
patients compared to healthy donors [24].
The present study was aimed at investigating the 
lncRNA expression profiles in a large and representative 
cohort of PC dyscrasia, including MGUS, SMM, MM, and 
PCL patients, and in normal bone marrow PC controls. We 
have identified deregulated lncRNAs putatively associated 
with MM pathogenesis and possibly linked to the accepted 
multi-step process underlining the different stages of the 
disease.
RESULTS
LncRNA expression profiling in plasma cell 
dyscrasia
The expression profiles of lncRNAs have been 
investigated by Gene 1.0 ST array in a large cohort 
of 268 patients included in two different datasets and 
representative of the major forms of plasma cell dyscrasia. 
The panel totally included 20 MGUS, 33 SMM, 170 MM, 
36 PCL patients and 9 normal bone marrow PCs samples. 
To be confident in detecting specifically lncRNAs, we 
applied a custom annotation pipeline able to remap the 
probes included in the original array to distinct lncRNAs 
according to the LNCipedia-v3.1 database (see Methods 
and Figure 1). Such a strategy allowed us to investigate 
the expression levels of 1852 well-annotated and specific 
human lncRNAs.
To determine whether the natural grouping of 
lncRNAs expression profiling could be associated with 
a specific clinical entity, we performed an unsupervised 
analysis using conventional hierarchical agglomerative 
clustering of the 230 lncRNAs whose average change in 
expression levels varied at least 1.5-fold from the mean 
across the dataset (Figure 2). Notably, we found that all 
normal controls clustered together (cluster in the green 
box, P <0.0001), as did 19 of 20 MGUS cases (cluster in 
the blue box, P = 0.0011) and SMM patients (P = 0.0049). 
Notably, the lncRNAs strongly upregulated in normal 
samples (Figure 2, black box) are located in chromosomal 
regions, such as 14q32, 2p, and 22p, coding for the highly 
variable portions of the immunoglobulin genes or for 
IGV pseudogenes. We related this to the highly complex 
transcriptional activity of these regions in normal PCs to 
achieve polyclonal antibody repertoire, therefore excluded 
these transcripts from further analyses.
Next, we compared normal samples with MGUS, 
SMM, MM or PCL patients, and identified a set of 
160 lncRNAs showing highly significant differential 
expression between normal PCs and those from the four 
different clinical entities (Supplementary Table S1). In 
particular, among this lncRNA panel, six transcripts 
were common to all the comparisons, whereas 25 
lncRNAs resulted from at least three analyses (Table 1). 
Among these 31 lncRNAs, 19 were upregulated in the 
pathological samples compared to normal plasma cells; 
notably lnc-SCYL1-1, also known as MALAT1. This 
group also includes lnc-MON2-2, lnc-PTPDC1-7, and 
lnc-USP25-2, all of which overlapping host genes for 
members of the let-7 miRNA family, and lnc-USP25-2, lnc- 
APC6, lnc-LIPG-3, lnc-TRPV2-1 and lnc-C3orf25-2 that 
overlap host genes for small nucleolar RNAs (snoRNAs) 
molecules. Among the 19 upregulated lncRNAs, we found 
seven transcripts classified in Ensembl as pseudogenes; 
for each lncRNA/pseudogene, we looked for the 
corresponding putative parental gene when identifiable 
by the blat search (UCSC Blat tool at http://genome.ucsc.
edu/index.html). Specifically, as shown in Table 1, lnc-
C3orf25-2, lnc-MC2R-2, lnc-CHRDL2-3, lnc-SYT8-3, 
lnc-PAIP1-3, and lnc-ABCB5-3, are all pseudogenes of 
ribosomal protein encoding genes, whereas lnc-SAFB2-3 
is a pseudogene of the SNRPE gene, which encodes a 
protein belonging to the large family of small nuclear 
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ribonucleoproteins (snRNPs), the building blocks of the 
spliceosome complex. In addition, we found a significant 
upregulation of lnc-ANGPTL1-3 and lnc-RLIM-6 that 
map antisense to the Ras-specific guanine nucleotide-
releasing factor RALGPS2 and to the thyroid hormone 
transporter SLC16A2, respectively; and lnc-ARFIP1-5 
localizing antisense to the E3 ubiquitin ligase FBXW7 
gene but also overlapping the MIR4453 locus. Finally, lnc-
SENP5-4 and lnc–AP1M2-1 localize head to head to the 
nuclear cap binding protein NCBP2 gene, and interleukin 
enhancer binding factor 3 (ILF3), respectively. Among the 
12 lncRNAs downregulated in the pathological samples 
compared to normal plasma cells, we found lnc-SNURF-1 
and lnc-SNURF-3 that are host genes for SNORD115 and 
SNORD116 families. Two pseudogenes of the RN7SL 
gene at 14q21 were found also downregulated. This gene 
encodes the small cytoplasmic RNA component of the 
signal recognition particle (SRP) that associates with the 
ribosome and targets nascent proteins to the endoplasmic 
reticulum for secretion or membrane insertion. Other 
four pseudogenes are included in the downregulated 
group: lnc-STOM-7 that is a remnant of the Alpha-1,3-
galactosyltransferase (GGTA1) gene encoding an enzyme 
present in most mammals except man; lnc-HSFY2-10 
that is positioned in sense orientation to its parental CD24 
gene; lnc-CISH-3, and lnc-SEL1L3-6. Furthermore, we 
found the down-regulation of lnc-LRRC47-1, described 
below.
Figure 1: Custom annotation pipeline. Flow diagram highlighting the different steps for processing the Gene 1.0 ST array data to 
investigate lncRNAs in combined databases (GSE66293 and GSE47552).
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LncRNA expression in the different stages of the 
disease
In order to identify deregulated lncRNAs possibly 
associated with the different clinico-biological forms of 
the disease, we searched for lncRNAs whose expression 
was significantly and progressively increased/decreased 
from normal PCs to PCLs (Jonckheere–Terpstra test). 
As reported in Table 2 and Supplementary Figure S1, 
the expression levels of 15 lncRNAs progressively 
increased from normal to MGUS, SMM, MM and PCL 
samples. On the other hand, six lncRNAs displayed a 
significantly decreasing trend. From a structural point of 
view, the resulting 21 lncRNAs could be divided in two 
main categories: i.e. (i) lncRNAs that are transcribed as 
complex, interlaced networks of overlapping transcripts 
often including protein-coding genes (as specified in Table 
2, fourth column); and (ii) those located and transcribed 
within the intergenic stretches of the genome.
Representative of the first group was lnc-LRRC47-1, 
whose expression showed a significant decreasing trend 
being significantly downregulated in MGUS, MM and 
PCL samples as compared to normal control (see above). 
In details, lnc-LRRC47-1 could be transcribed in 23 
different transcripts, seven of which correspond to the 
reported TP73-AS1 transcripts that map antisense to the 
3’UTR of the tumor suppressor TP73 gene. In agreement 
with the previous analyses, we found a significant 
increasing expression trend of lnc-ANGPTL1-3, lnc-
RLIM-6, and lnc-SENP5-4 from normal to pathological 
samples. Among the first group, we have also identified 
lnc-WHAMM-2 and lnc-SERPINC1-1, also known as 
SNHG21 and GAS5, respectively, which are host genes 
for SNORD molecules, and both showing a significant 
positive expression trend. Finally, this group also included 
three pseudogenes, the above described lnc-HSFY2-10, 
lnc-SNX29P2-3 that maps antisense to the NPIPL1 gene 
encoding a nuclear pore complex-interacting protein 
member, and lnc-CPSF2-2, which is a pseudogene of 
Prothymosin alpha (PTMA) and is localized antisense to 
the thyroid hormone receptor interactor 11 (TRIP11) gene.
The second lncRNA group included 12 transcripts 
10 of which are pseudogenes. Among the nine with a 
significant increasing expression trend from normal PCs 
to PCLs, we found lnc-PNRC1-1, lnc-DLX5-4, and lnc-
ZC3H12B-10, which are all pseudogenes of the RN7SL 
gene. Lnc-SAFB2-3 and lnc-KIF20B-7 are pseudogenes 
of SNRPE and SNRPD2, respectively, which encode 
proteins included in the snRNPs; notably, the expression 
levels of these lncRNAs resulted significantly correlated 
with those of corresponding parental genes (Table 2, 
last column). Lnc-MC2R-2 and lnc-DNAJC16-1 are 
respectively processed pseudogenes of RPL36A gene 
and the transcription factor CHCHD2 that transactivates 
a conserved oxygen response element. Moreover, lnc-
WDR11-7 is a pseudogene of the RN7SK family genes, 
involved in RNA Polymerase II activity control.
Finally, we investigated whether the lncRNAs that 
were gradually deregulated through the progressive stages of 
PC dyscrasia were also related to the disease progression in 
the same patient. To this regard, Gene Expression Profiling 
(GEP) data from a limited proprietary paired cohort of 19 
MM patients at diagnosis and relapse/PCL progression 
corroborated the deregulated expression of lnc-SENP5-4, 
lnc-CPSF2-2, and lnc-LRRC47-1 during disease progression 
in this subset of patients (Supplementary Figure S2).
Figure 2: LncRNA expression profiling in plasma cell dyscrasia. Hierarchical clustering of the 268 samples using the 230 
most variable lncRNAs (patients in columns, lncRNAs in rows). The color scale bar represents the relative lncRNA expression changes 
normalized by the standard deviation. Color above the matrix indicates the type of samples: white, light blue, pink, yellow, and red represent 
Normal (N), MGUS, SMM, MM, and PCL samples, respectively. Specific types are enriched in colored sub-branches (see text). Black box 
identifies lncRNAs strongly upregulated in normal samples (see text).
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Table 1: Differentially expressed LncRNAs resulting from SAM analyses comparing N with MGUS, sMM, MM, or 
PCL patients 
lncRNA
N
M
G
U
S
SM
M
M
M
PC
L Chr ALIAS; 
OVERLAPPING 
TRANSCRIPTa
Corr. 
lncRNA- 
transcriptb
PsGc Putative 
Parental 
Gene
Corr. lncRNA- 
parental geneb
AC100793.1-1 ↑ ↓ ↓ ↓ ↓ 17q21 RAMP2-AS1     
ATL3-1 ↑ ↓ ↓ ↓ ↓ 11q13 C11orf95     
ADAP2-2 ↑ ↓ ↓ ↓ ↓ 17q11 RN7SL138P  M RN7SL 
(14q21)
NA
STOM-7 ↑  ↓ ↓ ↓ 9q33 GGTA1P  UP   
HSFY2-10 ↑  ↓ ↓ ↓ Yq11 CD24P4; S to 
CD24
NA PP CD24 
(Yq11)
NA
CISH-3 ↑ ↓  ↓ ↓ 3p21 ZNF652P1; AS to 
DOCK3
R=0.053 PP ZNF652 
(17q21)
R=0.65 p<2.2e-16
LRRC47-1 ↑ ↓  ↓ ↓ 1p36 TP73-AS1; AS to 
TP73
R=0.03    
SEL1L3-6 ↑ ↓ ↓  ↓ 4p15   UnP NA  
SEMA4B-4 ↑ ↓ ↓  ↓ 15q26      
PQLC2-5 ↑ ↓ ↓  ↓ 1p36 RN7SL277P; AS 
to CAPZB
R= - 0.26 M RN7SL 
(14q21)
NA
SNURF-1 ↑ ↓ ↓  ↓ 15q11
S to 
SNORD115-116 
family
NA    
SNURF-3 ↑ ↓ ↓  ↓ 15q11
S to 
SNORD115-116 
family
NA    
APC-6 ↓ ↑ ↑ ↑ ↑ 5q22
EPB41L4A-AS1; 
S to SNORA13
NA    
MON2-2 ↓ ↑ ↑ ↑ ↑ 12q14 S to Let7i NA    
ARFIP1-5 ↓ ↑ ↑ ↑ ↑ 4q13 AS to FBXW7, S 
to MIR4453
R=0.03 
(FBXW7)
   
PTPDC1-7 ↓  ↑ ↑ ↑ 9q22 AS to 
MIRLET7DHG
NA    
MC2R-2 ↓  ↑ ↑ ↑ 18p11   PP RPL36A 
(Xq22)
NA
SAFB2-3 ↓  ↑ ↑ ↑ 19p13 SNRPEP4  PP SNRPE 
(1q32)
R=0.5
p =0.030
SYT8-3 ↓  ↑ ↑ ↑ 11p15 RPL36AP39  PP RPL36A 
(Xq22)
NA
CHRDL2-3 ↓  ↑ ↑ ↑ 11q13   PP RPS12 
(6q23)
R=0.17
SCYL1-1 ↓  ↑ ↑ ↑ 11q13 MALAT1     
(continued )
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Table 2: LncRNAs significantly increased/decreased in the progressive forms of plasma cell dyscrasias 
  lncRNAs SENSE or ANTISENSE (S or AS) TO ANNOTATED TRANSCRIPTS  
T
R
E
N
D
lncRNAs 
q<0.05a
Chr ALIAS; 
OVERLAPPING 
TRANSCRIPTSb
Corr. 
lncRNA-
overlapping 
transcriptc
PsGd Putative 
Parental 
Gene
Corr. lncRNA- 
parental genec
↑ RLIM-6 Xq13 AS to SLC16A2 R=0.37
p=3.7e-10
   
↑ ANGPTL1-3 1q25 AS to RALGPS2
R=0.3
p=3.8e-08
   
↑ SENP5-4 3q29
NCBP2-AS2; S to 
NCBP2
R= - 0.054    
↓ LRRC47-1 1p36
TP73-AS1; AS to 
TP73
R=0.03    
↑ WHAMM-2 15q25
SNHG21; AS to 
FSD2
R= - 0.03    
lncRNA
N
M
G
U
S
SM
M
M
M
PC
L Chr ALIAS; 
OVERLAPPING 
TRANSCRIPTa
Corr. 
lncRNA- 
transcriptb
PsGc Putative 
Parental 
Gene
Corr. lncRNA- 
parental geneb
TRPV2-1 ↓  ↑ ↑ ↑ 17p11
LRRC75A-AS1; 
S to SNORD49B, 
49A, 65
NA    
LIPG-3 ↓  ↑ ↑ ↑ 18q21 SNHG22     
USP25-2 ↓  ↑ ↑ ↑ 21q21 S to SNORD74, 
MIR99AHG
NA    
C3orf25-2 ↓  ↑ ↑ ↑ 3q21 RPL32P3; S to 
SNORA7B
NA UnP RPL32 
(3p25)
R=0.47 p<2.2e-16
AP1M2-1 ↓  ↑ ↑ ↑ 19p13 ILF3-AS1     
ANGPTL1-3 ↓  ↑ ↑ ↑ 1q25 AS to RALGPS2 R=0.3
p=3.8e-08
   
SENP5-4 ↓  ↑ ↑ ↑ 3q29 NCBP2 -AS2     
PAIP1-3 ↓  ↑ ↑ ↑ 5p12 RPL29P12; AS to 
NNT
R= - 0.054 PP RPL29 
(3p21)
R=0.7 p<2.2e-16
ABCB5-3 ↓  ↑ ↑ ↑ 7p21 RPL23P8  PP RPL23 
(17q12)
NA
RLIM-6 ↓  ↑ ↑ ↑ Xq13 AS to SLC16A2 R=0.37 
p=3.7e-10
   
Arrows indicate lncRNA expression, upregulation (↑) or downregulation (↓), in the corresponding group. Chromosomal 
localization (Chr), alias name, and overlapping transcripts are indicated.
a Sense (S) to, or Antisense (AS) to overlapping transcripts; b Pearson correlation coefficient; NA =not available (not 
detected by the array); cPsG=Pseudogene; Ensembl type: PP= Processed Pseudogene; UP= Unitary Pseudogene; 
UnP= Unprocessed Pseudogene; M= miscellaneous RNA.
(continued )
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  lncRNAs SENSE or ANTISENSE (S or AS) TO ANNOTATED TRANSCRIPTS  
T
R
E
N
D
lncRNAs 
q<0.05a
Chr ALIAS; 
OVERLAPPING 
TRANSCRIPTSb
Corr. 
lncRNA-
overlapping 
transcriptc
PsGd Putative 
Parental 
Gene
Corr. lncRNA- 
parental genec
↑ lSERPINC1-1 1q25
GAS5; AS to 
ZBTB37
R= 0.29
p=1.1e-06
   
↓ SNX29P2-3 16p11 AS to NPIPL1 NA P NA  
↓ HSFY2-10 Yq11
CD24P4; S to 
CD24
NA PP CD24 
(Yq11)
NA
↑ CPSF2-2 14q32 AS to TRIP11 R= 0.063 PP PTMA 
(2q37)
R= - 0.32 
p=7.8e-08
   LINC     
T
R
E
N
D
lncRNAs
q<0.05 a
Chr ALIAS  PsGd
Putative 
Parental 
Gene
Corr. lncRNA- 
parental genec
↓ IRF2-3 4q35      
↓ VKORC1L1-3 7q11 RP13-254B10.1  PP NA  
↓ STOM-7 9q33 GGTA1P  UP NA  
↑ RALGAPB-1 20q11 SNHG11     
↑ MC2R-2 18p11 RP11-681N23.1  PP RPL36A 
(Xq22)
NA
↑ SAFB2-3 19p13 SNRPEP4  PP SNRPE 
(1q32)
R=0.5 p=0.030
↑ KIF20B-7 10q23 SNRPD2P1  PP SNRPD2 
(19q13)
R=0.79 p<2.2e-16
↑ DNAJC16-1 1p36
CHCHD2P6 
(447bp, and 462bp)
 PP CHCHD2 (7p11) NA
↑ WDR11-7 10q26 RN7SKP167 RNA  M RN7SK 
(6p12)
NA
↑ PNRC1-1 6q15 RN7SL336P  M RN7SL 
(14q21)
NA
↑ DLX5-4 7q21 RN7SL252P  M RN7SL 
(14q21)
NA
↑ ZC3H12B-10 Xq11 RN7SL799P  M RN7SL 
(14q21)
NA
Arrows indicate lncRNA expression (upregulation ↑/downregulation ↓), from N to PCL samples. Chromosomal localization 
(Chr), alias name, and overlapping transcripts are indicated.
a lncRNAs also found in Table 1 are in bold; b Sense (S) to, or Antisense (AS) to overlapping transcripts; c Pearson 
correlation coefficient; NA=not available (not detected by the array); d PsG=Pseudogene; Ensembl type: PP= Processed 
Pseudogene; UP= Unitary Pseudogene; UnP= Unprocessed Pseudogene; M= miscellaneous RNA.
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LncRNA expression profiling in MM molecular 
subgroups
Based on the commonly accepted notion of the great 
heterogeneity in MM patients, we aimed at identifying 
lncRNAs deregulation distinctive of the major MM 
molecular subgroups. We focused on the proprietary panel 
of 129 MM patients, which is completely characterized 
for the major molecular alterations, i.e. chromosomal 
translocations involving the immunoglobulin heavy 
chain (IGH) locus, hyperdiploid (HD) status, deletions 
of 13q, 17p13, and gain of 1q. As shown in Figure 
3 and Supplementary Table S2, among the 10 most 
differentially expressed lncRNAs in HD versus non HD 
(NHD) patients, we found nine upregulated lncRNAs 
that are all pseudogenes related to ribosomal protein 
coding genes; for these lncRNA-parental gene couples 
a highly positive correlation of their expression levels 
was found (Figure 3). Notably, in MM characterized 
by t(11;14) translocation the analysis unraveled the 
upregulation of lnc-LRRC47-1 and lnc-SEL1L3-6, and the 
downregulation of lnc-MC2R-2 and lnc-SPRYD7-2, the 
latter of which may have 25 putative transcripts, eight of 
which corresponding to DLEU2. Patients carrying t(4;14) 
translocation upregulated lnc-WHSC2-2, a pseudogene 
located in the intron 19 of MMSET gene, which encodes 
the histone methyltransferase deregulated as the result of 
t(4;14) translocation. Finally, MM samples with either 
the t(14;16) or t(14;20) translocations upregulated lnc-
LIPG-3, the host gene of SCARNA17, and lnc-JAM2-2, 
which overlaps the MIR155HG locus.
Considering MM samples with 1q gain lesion, 
they specifically upregulated 7 lncRNAs all of which 
are located in the amplified chromosomal region and 
include lnc-SERPINC1-1 (GAS5) and lnc-CD46-4 
that maps antisense to miR-102 gene. Patients with 
del13 significantly deregulated 14 lncRNAs, five of 
which reside on 13q14 region. It is worth mentioning 
the downregulation of lnc-SPRYD7-1, also known as 
DLEU2, whose expression significantly correlated with 
that of miR-15a and miR-16-1 located in the same region 
(Supplementary Figure S3). MM patients with del17 
upregulated 3 lncRNAs (Table 3).
Figure 3: Identification of lncRNA signatures characterizing distinct MM genetic subgroups. Heatmap of the differentially 
expressed lncRNAs in 129 MM patients stratified into the five molecular groups as specified in methods; black boxes indicate the ten 
most differentially expressed lncRNAs resulting from the supervised analysis comparing each subgroup versus the rest of the dataset. 
LncRNA expression levels in normal plasma cells are shown on the right. For each lncRNA, information about chromosomal localization 
(Chr), alias name, transcripts overlapping in sense or antisense (indicated as S or AS, respectively) direction, and the Pearson’s correlation 
coefficient between lncRNA and the overlapping transcript (when detected by the array) are indicated. For lncRNAs/pseudogenes, the 
last column reports the putative parental gene and the Pearson’s correlation coefficient between lncRNA and the parental gene expression 
when detected by the array. a Sense (S) to, or Antisense (AS) to overlapping transcripts; b NA indicates transcripts not detected by 
the array; c PsG =pseudogene; Ensembl type: PP= Processed Pseudogene; UP= Unitary Pseudogene; UnP= Unprocessed Pseudogene; 
M= miscellaneous RNA.
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Table 3: LncRNAs significantly deregulated in MM patients with del13, del17 or 1q gain
lncRNA
Sc
or
e(
d)
F
ol
d 
C
ha
ng
e
C
hr
ALIAS; 
OVERLAPPING 
TRANSCRIPTa
Corr. 
lncRNA-
overlapping 
transcriptb
PsGc Putative 
Parental 
Gene
Corr. 
lncRNA- 
parental 
geneb
    del17     
MEF2C-2 4.98 2.26 5q14
LINC00461; S to 
MIR9-2
NA    
TRPV4-1 4.04 2.16 12q24
FAM222A-AS1; AS 
to FAM222A
R= - 0.07    
ROPN1B-7 3.62 1.60 3q21 FAM86JP  PP FAM86C1 (11q13) R= 0.22
    1q gain     
TOR1AIP2-5 3.81 1.48 1q25      
ANGPTL1-3 3.78 1.38 1q25 AS to RALGPS2
R=0.3
p=3.8e-08
   
CD46-4 3.43 1.30 1q32 AS to miR-102 NA    
SERPINC1-1 3.24 1.38 1q25
GAS5; AS to 
ZBTB37
R= 0.29 
p=1.1e-06
   
HNRNPU-1 3.12 1.48 1q44 HNRNPU-AS1; AS to 
COX20
R= 0.18    
TRAF5-1 3.11 1.35 1q32 LINC00467     
ANKRD36BP1-1 2.90 1.30 1q24 ANKRD36BP1     
    del13     
NEK3-1 -4.07 0.70 13q14 MRPS31P5  UnP NA  
FAM60A-6 -3.95 0.68 12p11 S to OVOS2 NA    
FAM70B-1 -3.67 0.79 13q14 GAS6-AS1; AS to 
GAS6
R= - 0.28    
CYorf15A.1-2 -3.30 0.39 Yq11 TXLNG2P  UnP TXLNG 
(Xp22)
R= - 0.07
MTRNR2L1-4 -3.28 0.85 17p11   PP MT-ND2 NA
ZFYVE1-4 -3.03 0.87 14q24 RN7SL586P  M RN7SL 
(14q21)
NA
RNASEH1-7 -2.96 0.81 2p25
TMSB4XP2; AS to 
COLEC11
R= 0.19 UnP
TMSB4X 
(Xp22)
NA
KDM5D-3 -2.91 0.66 Yq11      
SLC7A1-1 -2.81 0.82 13q12
MTUS2-AS1; AS to 
MTUS2
R= 0.19    
SPRYD7-1 -2.70 0.72 13q14 DLEU2; AS to 
TRIM13
R= 0.09    
RCOR3-1 -2.67 0.87 1q32   PP RPS25 
(11q23)
NA
BACH1-2 -2.67 0.84 21q21
GRIK1-AS1, AS to 
GRIK1
R= 0.18    
CLYBL-1 -2.65 0.76 13q32 S to CLYBL R= 0.24    
POM121L2-2 3.77 1.80 6p22 ZNF204P  PP NA  
a Sense (S) to, or Antisense (AS) to overlapping transcripts; b Pearson correlation coefficient; NA =not available (not 
detected by the array); c PsG=Pseudogene; Ensembl type: PP= Processed Pseudogene; UP= Unitary Pseudogene; UnP= 
Unprocessed Pseudogene; M= miscellaneous RNA.
Oncotarget14823www.impactjournals.com/oncotarget
Correlation between lncRNA and gene 
expression levels
Based on expression levels analysis, we evaluated 
for each of the differentially expressed lncRNA reported 
in Tables 1-3: i) the correlation with annotated transcripts 
that mapped sense or antisense to it, i.e. a potential in cis 
regulation; and ii) the relationship between lncRNAs/
pseudogenes and matching parental genes. The results, 
reported in Tables 1-3, pointed out that pseudogenes are 
often co-expressed at variable levels with their putative 
parental gene. Furthermore, to gain evidences of lncRNAs 
that may potentially act on gene expression, we extended 
this correlation analysis to all the 17788 transcripts 
unambiguously detectable by the arrays. To be confident of 
identifying lncRNA-gene real interaction, we focused on 
correlation coefficient > 0.9, and found five lncRNAs that 
highly correlated with one or more genes (Table 4), all of 
them modulated between normal and pathological samples. 
Among these, besides lnc-cYorf15A.1-2 and KDM5D 
gene that map ~112 kb apart on chromosome Y, the other 
four lncRNAs correlated with genes located on different 
chromosomes, suggesting in trans interplay for such couples.
Quantitative RT-PCR validation of differentially 
expressed lncRNAs
The expression levels of six relevant lncRNAs found 
differentially expressed in our analyses were investigated 
by qRT-PCR performed in 60 MM samples for whom 
RNA material was available. Specifically, we validated the 
expression levels of the well-known MALAT1, GAS5, and 
DLEU2 lncRNAs. Furthermore PCR results confirmed 
the significant upregulation of GAS5 in samples with 1q 
gain lesion, and the downregulation of DLEU2 in patients 
carrying del13 (Figure 4A–4B). Likewise, we validated 
the expression of lnc-ANGPTL1-3, lnc-SENP5-4, and lnc-
LRRC47-1, found progressively deregulated in association 
with more aggressive forms of the disease (Figure 4C).
Functional annotation of MALAT1 signature in 
MM
Although we found several lncRNAs deregulated 
in the different form of PC dyscrasia, only a very few 
number have been functionally validated in biological and 
disease processes. Among these, we found MALAT1, the 
Table 4: Genes whose expression level highly correlate with that of lncRNAs resulting from SAM analyses 
lncRNA
N
M
G
U
S
SM
M
M
M
PC
L Chr ALIAS HIGHLY CORRELATED 
GENE
Corr. 
lncRNA- 
genea
C14orf49-4 ↑ ↓    14q32 SNHG10 RPL18A (19p13) 0.907
RYR2-5 ↓  ↑ ↑  1q43 RPL35P1 RPL35 (9q33) 0.918
TAMM41-3 ↑ ↓    3p25 RN7SL147P OCEL1 (occludin/ELL 
domain containing 1; 19p13)
0.905
CYorf15A.1-2 ↑    ↓ Yq11
Taxilin 
gamma 2, 
pseudogene
KDM5D (LYSINE-
SPECIFIC 
DEMETHYLASE 5D; 
Yq11)
0.943
        
USP9Y (UBIQUITIN-
SPECIFIC PROTEASE 9; 
Yq11)
0.910
HSFY2-10 ↑  ↓ ↓ ↓ Yq11 CD24P4
BPI (BACTERICIDAL 
PERMEABILITY-
INCREASING PROTEIN; 
20q11)
0.914
        
CEACAM8 
(CARCINOEMBRYONIC 
ANTIGEN-RELATED 
CELL ADHESION 
MOLECULE 8; 19q13)
0.923
Arrows indicate lncRNA expression, upregulation (↑) or downregulation (↓), in the corresponding group. Chromosomal 
localization (Chr), alias name are indicated.
a Pearson correlation coefficient
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Figure 4: Quantitative RT-PCR validation of lncRNA expression in 60 MM cases. A. Box plots of lnc-SPRYD7-1 and lnc-
SERPINC1-1 expression show a significant correlation with group membership based on Wilcoxon rank-sum tests (p-values are shown 
above each panel). The expression levels are represented as 2−ΔCt. B. MALAT1 expression validation; Pearson’s correlation coefficient 
was calculated between GEP data and quantitative RT-PCR results expressed as 2−ΔCt. C. Genomic map of lncRNAs (red) and antisense 
genes (blue) with custom primers (green) localization. Sense or antisense chromosomal position (St+ or St-, respectively) are specified. 
For lnc-LRRC47-1, the scheme was limited to longer transcripts. Pearson’s correlation coefficient was calculated between GEP data and 
quantitative RT-PCR results expressed as 2−ΔCt.
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abundant nuclear-retained lncRNA found overexpressed 
in several cancers associated with high proliferation and 
metastasis, although the underlying mechanism(s) behind 
this deregulation and its significance in tumorigenesis is 
still poorly understood. Our data demonstrates a significant 
overexpression of MALAT1 in tumor samples compared 
to healthy controls (Figure 5A). To gain insight into the 
role of MALAT1 in MM, we focused on the proprietary 
MM group (due to the absence of any bias related to 
sample molecular characteristics) and looked for the gene 
expression signature associated with MALAT1 expression. 
Specifically, we ranked patients in four classes based on 
MALAT1 expression level. Next, by comparing the less 
(I quartile) with the most (IV quartile) expressing patients, 
we found 518 genes differentially expressed between the 
two groups that appeared to be gradually modulated in the 
four quartiles (Figure 5B and Supplementary Table S3). 
Functional enrichment analysis of the 518 deregulated 
genes using ToppGene evidenced 88 significantly 
enriched pathways, many of which attributable to mRNA 
maturation, proteasome degradation, cell cycle processes, 
and p53-dependent G1/S DNA damage checkpoint 
(Supplementary Table S4). In addition, Gene Set 
Enrichment Analysis (GSEA) was used to identify a priori 
defined sets of genes showing concordant modulation 
between patients with low and high MALAT1 expression 
level. Notably, GSEA analysis identified 13 gene sets 
(Figure 5C and Supplementary Table S5) among which 
the pathway associated with p53-mediated DNA damage 
response was highly enriched in MM group expressing 
less MALAT1 (Figure 5D).
DISCUSSION
LncRNAs are an emerging field of investigation as 
they are suggested to regulate key biological processes, 
including cellular proliferation and differentiation, and 
their aberrant expression being strongly associated with 
cancer [25].
Figure 5: MALAT1 expression deregulation in MM patients. A. Box plot of MALAT1 expression level in 9 N, 20 MGUS, 33 
SMM, 170 MM, and 36 PCL samples, as detected by GEP; p-value was calculated by Kruskal-Wallis rank sum test. B. Heatmap of the 518 
differentially expressed lncRNAs identified by comparing the first vs fourth quartile of 129 MM patients stratified into four groups based on 
MALAT1 expression level. C. Gene sets significantly up- and down-regulated in MALAT1 quartile IV versus I. Gene sets were selected on 
nominal p-value<0.01 and are ordered according to NES value. D. Enrichment plot of “DNA damage response signal transduction resulting 
in induction of apoptosis” gene set detected by GSEA. The green curves show the enrichment score and reflect the degree to which each 
gene (black vertical lines) is represented at the bottom of the ranked gene list. Genes contributing to the core enrichment in the gene set are 
indicated in bold.
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To the best of our knowledge, this is the first report 
describing the global expression profiles of lncRNAs 
in a large cohort of samples representing all the major 
different forms of plasma cell dyscrasias. Our study 
identified 31 lncRNAs that were specifically deregulated 
in this pathology compared to normal bone marrow PC 
controls (Table 1). In particular, we found six lncRNAs 
deregulated in all the different clinical forms of the 
disease, whereas 18 others appear associated with more 
advanced phases of the disease, as their expression in 
MGUS samples does not differ significantly from normal 
controls. A very notable example among lncRNAs found 
upregulated in pathological samples, is MALAT1 that has 
been widely reported to be upregulated in a large variety 
of solid tumors in association with progression and cancer 
metastasis [21]. It may be surprising that five lncRNAs 
are significantly downregulated in MGUS, SMM and 
PCL groups but not in MM one. This finding may be 
explained by the great heterogeneity of the MM patient. 
In agreement with this hypothesis, three out of the five 
lncRNAs, specifically lnc-SNURF-1, lnc-SNURF-3, and 
lnc-SEL1L3-6, were significantly deregulated in distinct 
MM subgroups (Supplementary Table S2).
Notably, we identified 21 lncRNAs whose 
expression was progressively deregulated in association 
with the increased aggressiveness of the disease (Table 
2). Among these, the expression levels of lnc-SENP5-4, 
lnc-CPSF2-2, and lnc-LRRC47-1 were found to be 
significantly different in a cohort of 19 MM patients at 
diagnosis compared to the corresponding relapse/PCL 
progressed phases (Supplementary Figure S2), a finding 
that further supports the previous evidence. In addition, 
a recent study investigating lnc-LRRC47-1 in MM, 
confirmed its progressive downregulation from normal 
PCs to MGUS and symptomatic disease, which appeared 
independent from the methylation status of its promoter 
[26]. Thus, it is conceivable that these lncRNAs may 
have a role in the progression of the disease. Furthermore, 
disease progression is associated with the upregulation 
of GAS5 and lnc-ANGPTL1-3, both located at 1q25; 
this finding is in line with the GEP-model for high-risk 
MM that is enriched in overexpressed genes mapping 
to chromosome 1q [27]. Certainly the role of GAS5 in 
MM deserves further studies considering that almost all 
the existent literature describes GAS5 down-regulation 
in different cancers, above all solid tumors; according to 
existing data, GAS5 both inhibits the proliferation and 
promotes the apoptosis of multiple cell types, consistent 
with a tumor suppressor role (reviewed in [28]). To date, 
GAS5 overexpression in tumor has been reported only 
in mesothelioma [29], where the Authors hypothesized, 
as a possible explanation of the discrepancy, that high 
GAS5 expression in that cellular milieu does not only 
control cell cycle but also act as a natural sponge for 
miRNAs. GAS5 has been demonstrated as host gene for 
snoRNA molecules that traditionally function as guide 
for the post-transcriptional modification of ribosomal 
and some spliceosomal RNAs and are supposed to play 
a role in alternative splicing processes [30]. According 
to this, we may hypothesize that in PC dyscrasia GAS5 
deregulation affects processes that represent oncogenic 
mechanisms in MM.
In the context of MM, we demonstrated that 
deregulated patterns of lncRNAs expression are 
associated with distinct molecular subtypes, as it has 
long been commonly accepted for mRNAs, miRNAs, 
and snoRNAs [30–33]. Despite the fact that the 
mechanism and the function of lncRNAs, as well as 
the consequences of their deregulation remain to be 
fully clarified, the transcriptional lncRNA signature of 
some MM subgroups may not be surprising. In fact, 
the most upregulated lncRNAs in HD tumors are all 
pseudogenes of parental ribosomal protein coding 
genes, with which they are co-expressed (Figure 3). 
These findings are in line with the global up-regulation 
of the translational machinery, including genes involved 
in protein biosynthesis, characterizing this molecular 
group [34]. Based on the suggestion that the presence of 
pseudogenes may serve to modulate the activity of their 
parental gene [35, 36], it is feasible that these lncRNAs/
pseudogenes may act as indirect post-transcriptional 
regulators decoying ncRNA, in particular miRNAs 
that target the parental gene [36]. Very interesting is 
also the lnc-JAM2-2, found to be upregulated in MM 
patients with MAF deregulation; this lncRNA overlaps 
MIR155HG gene, i.e. the host gene of the miR-155 
found also upregulated in translocated MAF samples 
[31]. Considering MM patients carrying t(4;14), the 
upregulation of lnc-WHSC2-2 that maps intronic and 
antisense to the translocation target gene MMSET, is 
relevant. Notably, the consistent deregulation of lnc-
WHSC2-2 in translocated MM resembles that of the 
snoRNA ACA11 that maps in the adjacent 3’ intron of 
MMSET on the sense strand [30, 37]. It is conceivable 
that, as reported for ACA11 [37], lnc-WHSC2-2 may 
be a critical target of the t(4;14) translocation in MM 
with a specific oncogenic role. Finally, the 1q-gain MM 
group showed significantly upregulated seven lncRNAs 
all located at 1q region, suggesting that gene dose effect 
may also be a mechanism behind lncRNAs deregulation.
Although every resultant lncRNA from our 
study warrants further investigation to elucidate its 
possible biological role, some of them are suggestive 
of a pathological function merely by relying on their 
genomic position. In particular, the overexpression of lnc-
PTPDC1-7, lnc-USP25-2, and lnc-MON2-2 that overlap 
host genes for members of the let-7 family may somehow 
be related to this miRNA downregulation often detected 
in cancer [38]. Other lncRNAs lie in proximity of genes 
already known in cancer and thus potentially involved in 
their regulation, for example lnc-LRRC47-1, which may 
regulate the tumor suppressor TP73 gene [39].
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At present, there is strong evidence of a major 
role for lncRNAs in tumorigenesis based on several 
hundred lncRNAs already identified as being aberrantly 
expressed in cancer [25]. However, only a few of these 
lncRNAs have been functionally validated in normal 
and pathological biologic processes. Among these, 
MALAT1 was reported to regulate cellular proliferation 
by modulating the expression and/or pre-mRNA 
processing of cell cycle-regulated transcription factors; 
moreover, transient overexpression of MALAT1 enhanced 
cellular proliferation in cell lines and tumor formation 
in nude mice, while its depletion in tumor cells reduced 
tumorigenicity [40, 41]. In line with these findings, our 
data evidenced a significant overexpression of MALAT1 in 
tumor samples compared to healthy controls. Interestingly, 
functional annotation of the MALAT1 signature in MM 
identified enriched pathways linked to mRNA maturation, 
proteasome degradation, cell cycle processes, and p53-
dependent G1/S DNA damage checkpoint. In addition, 
GSEA results showed that the pathway associated 
with p53-mediated DNA damage response was highly 
enriched in MM group less expressing MALAT1. This 
evidence suggests that p53 may be an important effector 
of MALAT1 function in PCs as it has been described in 
fibroblast [42].
In conclusion, our study reported many lncRNAs 
deregulated in the different forms of plasma cell dyscrasia. 
The challenge now and in the future is to identify the truly 
oncogenic and functionally relevant lncRNAs.
MATERIALS AND METHODS
Samples
The study was performed in a cohort of 268 patients 
included in two different datasets, and representative of all 
the major forms of plasma cell dyscrasia. Specifically, the 
proprietary dataset publicly available at the NCBI Gene 
Expression Omnibus repository (accession #GSE66293) 
included 4 normal controls (Voden, Medical Instruments 
IT), 129 MM, 24 pPCL, and 12 sPCL patients; the other 
[43] included 5 normal controls, 20 MGUS, 33 SMM, and 
41 MM patients, whose expression data were publicly 
available (accession #GSE47552). With the exception of 
sPCL, the cohort consists of newly-diagnosed patients. 
PCs were purified from bone marrow samples using 
CD138 immunomagnetic microbeads (MidiMACS 
system, Miltenyi Biotec, Auburn, CA) and the purity of 
the positively selected PCs was >90% in all cases.
The proprietary 129 MM tumors employed for 
the study were representative of the major molecular 
characteristics of the disease. Samples were characterized 
for the presence of the most frequent chromosomal 
translocations and the ploidy status based on fluorescence 
in situ hybridization (FISH) evaluation criteria, as 
previously described [34]. Specifically, forty-eight showed 
a HD status; thirty-four samples were characterized by 
the t(11;14) or t(6;14) translocations; nineteen had the 
t(4;14) translocation; six had either the t(14;16) or t(14;20) 
translocations; and twenty-two did not fall into any of the 
other groups. Deletions of 17p13, 13q14 and gain of 1q 
were also evaluated by FISH.
Expression profiling
GEP of the 268 samples was generated using 
GeneChip® Gene 1.0 ST Array (Affymetrix Inc., Santa 
Clara, CA) as previously described [33] (Supplementary 
Methods). Then, we applied a custom pipeline (Figure 1) 
to detect specific lncRNAs. Log2-transformed expression 
values were extracted from CEL files and normalized 
using RMA procedure in Expression Console Software 
(Affymetrix, Inc.) at the probe cluster ID annotation level. 
Cross-hybridization probes were filtered-out. To avoid 
potential biases due to the mixing of two different datasets, 
a quality control of the array datasets was performed. In 
particular, before proceeding, to prevent the inclusion of 
low-quality or non-reproducible data, normalized unscaled 
standard error (NUSE) and relative log-expression (RLE) 
distributions were generated in aroma.affymetrix package 
for all samples (samples would be removed if the 25th 
or the 75th percentile of NUSE and RLE exceeded the 
value of ±1.05 or ±0.5, respectively; Supplementary 
Figure S4A-B). Then, we combined annotated probes 
with both Ensembl transcripts (GRCh37/hg19 assembly) 
and lncRNAs from LNCipedia repository (http://www.
lncipedia.org/), based on the chromosome localization of 
the target sequence identified by each probe; afterwards, 
we considered only probes univocally referable to 
lncRNA transcripts (i.e. that do not overlap with Ensembl 
transcripts). To summarize probes related to each lncRNA, 
we considered their median expression value. Finally, we 
added a further step of batch adjustment using the sva 
function in the homonymous package of the R software, to 
avoid any possible cohort-specific bias due to the merging 
of different datasets. Through this annotation pipeline, 
we selectively detected 1852 lncRNAs from LNCipedia 
database.
The principal component analysis (PCA) of the 
samples was performed by singular value decomposition 
of the considered data expression matrix using the 
prcomp function in the stats package, and the results 
were visualized using the plot3d function in the rgl 
package of the R software (Supplementary Figure S4C). 
Supervised analyses were carried out using the Significant 
Analysis of Microarrays software version 5.00 [44] using 
the web application provided in the shiny package of 
the R software (https://github.com/MikeJSeo/SAM). 
The cutoff point for statistical significance (at a q-value 
0) was determined by tuning the Δ parameter on the 
false discovery rate and controlling the q-value of the 
selected probes. Hierarchical agglomerative clustering 
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of patients based on the most significant probesets 
found was performed adopting Pearson's correlation and 
average as distance and linkage methods, respectively. 
DNA-Chip Analyzer software (dChip) [45] was used 
to perform clustering and graphically represent it. The 
list of differentially expressed genes was submitted to 
the ToppGene Suite portal (http://toppgene.cchmc.org) 
for functional enrichment analysis using the ToppFun 
application [46]. Microarray data were globally analyzed 
by Gene Set Enrichment Analysis (GSEA) [47]. MiRNA 
expression data was available for 125 samples out of 
our series (GSE70254 and GSE73452) generated using 
GeneChip® miRNA 3.0 Array (Affymetrix Inc., Santa 
Clara, CA) as previously described [48].
Quantitative real-rime PCR (qRT-PCR)
For qRT-PCR, 100 ng of total RNA underwent 
reverse transcription using random primer mix and 
reagents from INVITROGEN (Life Technologies, Foster 
City, CA). Real-time PCR was performed in triplicate 
using TaqMan® Non-coding RNA Assays (Hs00273907_
s1, Hs03671981_s1, and Hs00863925_m1 for MALAT1, 
GAS5, and DLEU, respectively) together with the 
TaqMan® Fast Universal PCR Master Mix on an Applied 
Biosystems 7900 Sequence Detection System. RNA 
samples were normalized based on the house-keeping 
18S rRNA. Real-time PCR to validate lnc-LRRC47-1, 
lnc-ANGPTL1-3, and lnc-SENP5-4 was performed using 
10 ng of total RNA and SYBR™ Green master mixes 
with custom primers (Supplementary Table S6). RNA 
samples were normalized based on the GAPDH gene. 
The threshold cycle (C
T
) was defined as the fractional 
cycle number at which the fluorescence passes the fixed 
threshold. LncRNA expression was relatively quantified 
using the 2-ΔCt method (Applied Biosystems User Bulletin 
No. 2), and expressed as the relative quantity of target 
lncRNA normalized to the house-keeping 18S rRNA.
Statistical analysis
Conventional statistical procedures were applied 
using standard packages of the R software (Kendall 
τ correlations and Wilcoxon rank-sum tests). The 
Jonckheere–Terpstra test function was used in the clinfun 
package to investigate the significance of the trend from 
normal donors through PCL cases in the expression levels 
of the selected lncRNA list generated on Gene 1.0 ST 
array. For robustness, to reduce biases that might be due 
to numerical imbalances within the groups (with the MM 
group being largely overrepresented) and to gain the most 
significant trends, an additional criterion was imposed 
that only steadily ascending or descending median values 
were allowed. In addition, a differential expression should 
be observed in at least 1 condition (Kruskal–Wallis tests 
using the appropriate function in the stat package in R 
software). The Benjamini and Hochberg correction was 
used to adjust significance of multiple tests (adjusted P 
< 0.05).
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